Structure Therapeutics (GPCR) Receivables (2025)

Structure Therapeutics (GPCR) recorded quarterly Receivables of $200.0 million in Q4 2025.

Structure Therapeutics (GPCR) Receivables (2025) Analysis & Trends

Structure Therapeutics' Receivables history runs 1 years deep, the most recent figure standing at $200.0 million for Q4 2025.

In Q4 2025, Receivables changed N/A year-over-year to $200.0 million; the TTM figure through Dec 2025 stood at $200.0 million (changed N/A YoY), while the FY2025 annual figure was $200.0 million, changed N/A from the prior year.
Receivables was $200.0 million for Q4 2025 at Structure Therapeutics.
In the past five years, Receivables ranged from a high of $200.0 million in Q4 2025 to a low of $200.0 million in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	13.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	2.00 Bn
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Structure Therapeutics	9.35 Bn	9.35 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2025	200.00 Mn